SMRT Sequencing Enables High-Throughput Identification of Novel AAVs from Capsid Shuffling and Directed Evolution
Authors:
- Widler CasyWCWidler Casy
- Irvin T. GarzaIGIrvin T. Garza
- Xin ChenXCXin Chen
- Thomas DongTDThomas Dong
- Yuhui HuYHYuhui Hu
- Mohammed KanchwalaMKMohammed Kanchwala
- Cynthia B. TryggCTCynthia B. Trygg
- Charles ShyngCSCharles Shyng
- Chao XingCXChao Xing
- Bruce A. BunnellBruce A. Bunnell
- Stephen E. BraunSBStephen E. Braun
- Steven J. GraySGSteven J. Gray
Open Access
Abstract
The use of AAV capsid libraries coupled with various selection strategies has proven to be a remarkable approach for generating novel AAVs with enhanced and desired features. The inability to reliably sequence the complete capsid gene in a high-throughput manner has been the bottleneck of capsid engineering. As a result, many library strategies are confined to localized and modest alterations in the capsid, such as peptide insertions or single variable region (VR) alterations. The caveat of short reads by means of next-generation sequencing (NGS) hinders the diversity of capsid library construction, shifting the field away from whole-capsid modifications. We generated AAV capsid shuffled libraries of naturally occurring AAVs and applied directed evolution in both mice and non-human primates (NHPs), with the goal of yielding AAVs that are compatible across both species for translational applications. We recovered DNA from the tissues of injected animal and used single molecule real-time (SMRT) sequencing to identify variants enriched in the central nervous system (CNS). We provide insights and considerations for variant identification by comparing bulk tissue sequencing to that of isolated nuclei. Our work highlights the potential advantages of whole-capsid engineering, as well as indispensable methodological improvements for the analysis of recovered capsids, including the nuclei-enrichment step and SMRT sequencing.Keywords
Funding Information
- National Institutes of Health (R01NS095867)
This publication has 57 references indexed in Scilit:
- Structure and Dynamics of Adeno-Associated Virus Serotype 1 VP1-Unique N-Terminal Domain and Its Role in Capsid TraffickingJournal of Virology, 2013
- Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8Journal of Virology, 2012
- Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9Journal of Virology, 2012
- Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV VectorMolecular Therapy, 2012
- Production of Recombinant Adeno‐Associated Viral Vectors and Use in In Vitro and In Vivo AdministrationCurrent Protocols in Neuroscience, 2011
- Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene TransferMolecular Therapy, 2011
- A viral assembly factor promotes AAV2 capsid formation in the nucleolusProceedings of the National Academy of Sciences, 2010
- Directed Evolution of a Novel Adeno-associated Virus (AAV) Vector That Crosses the Seizure-compromised Blood–Brain Barrier (BBB)Molecular Therapy, 2010
- Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscleNature Biotechnology, 2010
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008